{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011164","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2022-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.040745+00:00","generated_at":"2026-06-25T04:56:24.932513+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sarepta shareholders approve 2.5M share increase to 2018 equity plan","bullets":["Shareholders approved 2018 Plan Amendment, increasing authorized shares by 2.5M to 10,687,596.","All four Class I director nominees elected: Boor, Chambers, Ingram, Wigzell.","Advisory say-on-pay passed with 62,746,933 for (93.2% of votes cast).","KPMG ratified as independent auditor for 2022 with 73,729,807 for.","Equity plan vote: 62,644,364 for, 4,572,292 against, 55,530 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011164","json":"https://secwatch.observer/filing/0000950170-22-011164.json","markdown":"https://secwatch.observer/filing/0000950170-22-011164.md","text":"https://secwatch.observer/filing/0000950170-22-011164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017022011164/0000950170-22-011164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017022011164/srpt-20220602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:56:24.932513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}